Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2021 09:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment...
June 23, 2021 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN...
May 13, 2021 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology...
April 12, 2021 08:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety

AMX-818 is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated T cell engager) platform designed to improve the toxicity profile of T cell engagers for the treatment of HER2-expressing...
March 04, 2021 08:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline

Proceeds will fund advancement of the company’s pipeline of protease-activated T cell engagers and cytokines for the treatment of solid tumorsFunding round supported by top-tier crossover investor...
January 26, 2021 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
December 09, 2020 09:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020

– Data demonstrate potential of Amunix’s XPAT (XTENylated Protease-Activated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating...
September 17, 2020 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020

– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors – – Masked prodrug...
June 22, 2020 09:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II

Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
May 27, 2020 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality

MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...

Next Page keyboard_arrow_right